A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that accused three leading insulin manufacturers of charging excessive ...

Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

Novo Nordisk will invest around $1 billion to expand ... corporate expansion and site selection in Central-South America. Minnesota's economic landscape is as diverse as its workforce, which ...

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...